文拉法辛与艾司西酞普兰治疗抑郁症的循证药物经济学评价
x

请在关注微信后,向客服人员索取文件

篇名: 文拉法辛与艾司西酞普兰治疗抑郁症的循证药物经济学评价
TITLE:
摘要: 目的:系统评价文拉法辛与艾司西酞普兰治疗抑郁症的药物经济学效果。方法:以“文拉法辛”“艾司西酞普兰”“抑郁症”“抑郁发作”“抗抑郁”等作为关键词,计算机检索中国期刊全文数据库(CNKI)、维普中文期刊全文数据库(VIP)、万方医学数据库,检索时间为创库日期至2015年12月,筛选符合纳排标准的文拉法辛与艾司西酞普兰治疗抑郁症的相关文献。统计两组方案治疗抑郁症的痊愈率和汉密尔顿抑郁量表(HAMD)评分,并采用药物经济学中成本-效果分析法对其进行分析。结果:两组方案痊愈率和HAMD评分比较,差异均无统计学意义(P>0.05),故采用最小成本法进行分析。文拉法辛与艾司西酞普兰治疗抑郁症的成本分别为772.03、935.77元。结论:文拉法辛与艾司西酞普兰治疗抑郁症的疗效相当,但文拉法辛方案更为经济。
ABSTRACT: OBJECTIVE: To systematically evaluate the pharnacoeconomic effect of venlafaxine and escitalopram in the treatment of depressive disorders. METHODS: Using “venlafaxine” “escitalopram” “depression” “depressive episode” “antidepressant” as key words, retrieved from CNKI, VIP and Wanfang database during base creation date to Dec. 2015, related literatures about venlafaxine and escitalopram in the treatment of depressive disorders were selected. The cure rate of two therapy plans for depressive disorders and HAMD score were analyzed statistically by cost-effectiveness analysis of pharnacoeconomics. RESULTS: There was no statistical significance in cure rate and HAMD score between 2 groups (P>0.05), so minimum-cost analysis was adopted. The costs of venlafaxine and escitalopram in the treatment of depressive disorders were 772.03 yuan and 935.77 yuan. CONCLUSIONS: Therapeutic efficacy of venlafaxine is similar to that of escitalopram in the treatment of depressive disorders, but the former scheme is more economical.
期刊: 2017年第28卷第11期
作者: 杜彪,杜扬,谢星星,范小冬,张春燕,孔文强
AUTHORS: DU Biao,DU Yang,XIE Xingxing,FAN Xiaodong,ZHANG Chunyan,KONG Wenqiang
关键字: 文拉法辛;艾司西酞普兰;抑郁症;最小成本分析;循证药物经济学评价
KEYWORDS: Venlafaxine; Escitalopram; Depressive disorder; Cost-minimization analysis; Evidence-based pharnacoeconomic evaluation
阅读数: 474 次
本月下载数: 10 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!